Carolina S. Ilkow

Ottawa Hospital Research Institute

Affiliated withOttawa Hospital Research Institute University of Ottawa

Research Area

Immunology and Infection

Biography

Carolina S. Ilkow has not added Biography.
If you are Carolina S. Ilkow and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title	2021
Publication title Cited by 2	2021

Other Publications

Article	Year
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 24695102	2014
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 25807289	2015
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature medicine\| PubMed ID: 25894825	2015
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer cell\| PubMed ID: 26212250	2015
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular therapy oncolytics\| PubMed ID: 27909702	2016
A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma. Cancer cell\| PubMed ID: 28810141	2017
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. EBioMedicine\| PubMed ID: 29724655	2018
Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. Journal for immunotherapy of cancer\| PubMed ID: 29921327	2018
Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 31486045	2020
Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis. Cancers\| PubMed ID: 32722184	2020
Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. Membranes\| PubMed ID: 32872641	2020
Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. Cytokine & growth factor reviews\| PubMed ID: 32958389	2020
Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation. Journal of cancer research and clinical oncology\| PubMed ID: 33555379	2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 33578036	2021
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. International journal of molecular sciences\| PubMed ID: 33668756	2021
SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. Biosensors & bioelectronics\| PubMed ID: 33706157	2021
A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. Nanomaterials (Basel, Switzerland)\| PubMed ID: 33809836	2021
Oncolytic Virus Immunotherapy. Cancers\| PubMed ID: 34359574	2021